Navigation Links
Faruqi & Faruqi, LLP is Investigating AmerisourceBergen Corporation on Behalf of its Shareholders

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential wrongdoing at AmerisourceBergen Corporation ("ABC" or the "Company") (NYSE: ABC).  The investigation focuses on whether certain officers and directors of ABC violated their fiduciary duties to the Company by failing to ensure that ABC had adequate internal controls to prevent the diversion of controlled substances to illegitimate channels.

(Logo -

Request more information now by clicking here:

On August 9, 2012, ABC, a prescription drug wholesaler, disclosed that it had received subpoenas from the U.S. Attorney's Office in New Jersey and the Drug Enforcement Agency ("DEA") involving the Company's processes for handling controlled substances.  The subpoenas are connected to a grand jury proceeding seeking documents about ABC's program for controlling and monitoring the diversion of controlled substances into illegitimate channels.  Furthermore, in June 2012, the West Virginia Attorney General filed a lawsuit against the Company alleging that ABC failed to provide effective controls and procedures to guard against the diversion of controlled substances for illegal purposes in West Virginia. 

Faruqi & Faruqi, LLP is a national law firm representing investors, consumers and companies in the prosecution of claims under state corporate and consumer laws and the federal securities and antitrust laws.  The firm is focused on providing exemplary legal services in complex litigation.  Founded in 1995, the firm maintains its principal office in New York City, with offices in Delaware, California, Florida and Pennsylvania.  The lawyers at Faruqi & Faruqi, LLP have demonstrated a clear commitment to championing the rights of shareholders and consumers nationwide.

If you are a current ABC shareholder, and you would like to discuss your legal rights, visit  You can also contact us by calling Beth A. Keller toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to


Faruqi & Faruqi, LLP
Beth A. Keller, Esq.
369 Lexington Avenue, 10th Floor
New York, NY 10017
Telephone: (877) 247-4292 or (212) 983-9330


Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In American Oriental Bioengineering Inc. To Contact The Firm Regarding The August 22, 2012 Lead Plaintiff Deadline
2. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
3. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
4. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
7. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
8. Healthy Vision & Contact Lenses - New Educational Resource Offers Important Advice On Safe Wear And Care Of Contact Lenses
9. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
10. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
11. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):